Tags

Type your tag names separated by a space and hit enter

Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group.
Osteoporos Int 1999; 9(4):358-66OI

Abstract

A total of 277 early postmenopausal women were enrolled in this placebo-controlled 2-year study to examine the efficacy of a matrix transdermal 17beta-estradiol system, at three different dosages (25, 50 and 75 mg/day) combined with sequential oral dydrogesterone 20 mg/day, in preventing bone loss. At 2 years, the difference from placebo in percentage change from baseline of L1-4 lumbar spine bone mineral density (BMD) (assessed by dual-energy X-ray absorptiometry) was 4.7% +/- 0.7% with estradiol 25 mg/day, 7.3% +/- 0.7% with estradiol 50 mg/day and 8.7% +/- 0.7% with estradiol 75 mg/day (all values mean +/- SEM). There were also significant increases in femoral neck, trochanter and total hip BMD with all doses of estradiol compared with placebo. Additionally, most patients had a significant gain (increase greater than 2.08%) in lumbar spine bone mass compared with placebo. Patients who received estradiol also experienced clinically significant and dose-related decreases in total serum osteocalcin, serum bone alkaline phosphatase and urinary C-telopeptide, with all three markers of bone turnover returning to premenopausal levels. Estradiol was well tolerated during the 2-year treatment period. Transdermal estradiol is effective and well tolerated at dosages between 25-75 mg/day in the prevention of bone loss in postmenopausal women; 25 mg/day offers an effective option for those women who cannot tolerate higher doses.

Authors+Show Affiliations

Southampton General Hospital, Southampton, UK.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

10550454

Citation

Cooper, C, et al. "Matrix Delivery Transdermal 17beta-estradiol for the Prevention of Bone Loss in Postmenopausal Women. the International Study Group." Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, vol. 9, no. 4, 1999, pp. 358-66.
Cooper C, Stakkestad JA, Radowicki S, et al. Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group. Osteoporos Int. 1999;9(4):358-66.
Cooper, C., Stakkestad, J. A., Radowicki, S., Hardy, P., Pilate, C., Dain, M. P., & Delmas, P. D. (1999). Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group. Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 9(4), pp. 358-66.
Cooper C, et al. Matrix Delivery Transdermal 17beta-estradiol for the Prevention of Bone Loss in Postmenopausal Women. the International Study Group. Osteoporos Int. 1999;9(4):358-66. PubMed PMID: 10550454.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group. AU - Cooper,C, AU - Stakkestad,J A, AU - Radowicki,S, AU - Hardy,P, AU - Pilate,C, AU - Dain,M P, AU - Delmas,P D, PY - 1999/11/7/pubmed PY - 1999/11/7/medline PY - 1999/11/7/entrez SP - 358 EP - 66 JF - Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA JO - Osteoporos Int VL - 9 IS - 4 N2 - A total of 277 early postmenopausal women were enrolled in this placebo-controlled 2-year study to examine the efficacy of a matrix transdermal 17beta-estradiol system, at three different dosages (25, 50 and 75 mg/day) combined with sequential oral dydrogesterone 20 mg/day, in preventing bone loss. At 2 years, the difference from placebo in percentage change from baseline of L1-4 lumbar spine bone mineral density (BMD) (assessed by dual-energy X-ray absorptiometry) was 4.7% +/- 0.7% with estradiol 25 mg/day, 7.3% +/- 0.7% with estradiol 50 mg/day and 8.7% +/- 0.7% with estradiol 75 mg/day (all values mean +/- SEM). There were also significant increases in femoral neck, trochanter and total hip BMD with all doses of estradiol compared with placebo. Additionally, most patients had a significant gain (increase greater than 2.08%) in lumbar spine bone mass compared with placebo. Patients who received estradiol also experienced clinically significant and dose-related decreases in total serum osteocalcin, serum bone alkaline phosphatase and urinary C-telopeptide, with all three markers of bone turnover returning to premenopausal levels. Estradiol was well tolerated during the 2-year treatment period. Transdermal estradiol is effective and well tolerated at dosages between 25-75 mg/day in the prevention of bone loss in postmenopausal women; 25 mg/day offers an effective option for those women who cannot tolerate higher doses. SN - 0937-941X UR - https://www.unboundmedicine.com/medline/citation/10550454/Matrix_delivery_transdermal_17beta_estradiol_for_the_prevention_of_bone_loss_in_postmenopausal_women__The_International_Study_Group_ L2 - https://dx.doi.org/10.1007/s001980050159 DB - PRIME DP - Unbound Medicine ER -